Translating HSP90 Inhibition into Cancer Therapy: Mechani...
2025-10-22
This article explores the mechanistic underpinnings and strategic opportunities for translational researchers leveraging HSP90 inhibition in oncology. Anchored by the synthetic geldanamycin analogue 17-AAG (Tanespimycin), we traverse the current landscape of chaperone-targeted therapeutics, integrate lessons from recent discoveries in cell death regulation, and articulate how the field can evolve beyond established paradigms. Unlike conventional product summaries, this thought leadership piece forges connections between mechanistic cell biology, advanced pharmacology, and actionable guidance for translational teams.
SU 5402: Precision Receptor Tyrosine Kinase Inhibitor in ...
2025-10-21
SU 5402 stands out as a potent and versatile receptor tyrosine kinase inhibitor, enabling researchers to dissect complex signaling pathways in cancer biology and neuronal viral latency. Its robust inhibition of FGFR3 phosphorylation and downstream ERK1/2 and STAT3 pathways empowers novel experimental designs, with actionable troubleshooting strategies for reproducible results across oncology and neurovirology models.
557 records 38/38 page Previous First page 上5页 363738